Salubris(SZ:002294) Ge Long Hui A P P·2026-01-21 12:10Core Viewpoint - The company, Xinlitai (002294.SZ), announced a change in the use of raised funds for its clinical research projects, reallocating part of the funds from one project to another while ensuring the original project continues [1] Group 1: Fund Allocation Changes - The company plans to change the use of part of the raised funds from the "S086 Sacubitril/Valsartan Calcium China II/III Phase Clinical Research and Market Registration Project" to a new project focused on "Innovative Hypertension Drugs II/III Phase Clinical Research and Market Registration Project" [1] - The total investment for the new project is set at 525.71 million yuan, with 301 million yuan coming from the raised funds, accounting for 15.58% of the total raised funds [1] - The company will cover any shortfall in funding for the new project with its own funds [1] Group 2: Project Timeline Adjustments - Despite the changes in fund allocation, the S086 project will continue to be implemented, with the company also planning to adjust the expected completion date of the S086 project to March 2028 [1]